HIV, HTLV AND DRUG ABUSE

HIV、HTLV 和药物滥用

• 批准号: 7716239
• 负责人: MARK A BEILKE
• 金额: $ 6.33万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-21 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716239
• 关键词: Age; Ambulatory Care Facilities; Anti-Retroviral Agents; CD4 Lymphocyte Count; Categories; Cohort Studies; Computer Retrieval of Information on Scientific Projects Database; Detection; Disease; Drug abuse; Enrollment; Enzyme-Linked Immunosorbent Assay; Funding; Gender; Genetic Transcription; Grant; HIV; HIV-1; HTLV-1 Infection; Highly Active Antiretroviral Therapy; Human T-lymphotropic virus 1; Human T-lymphotropic virus 2; Individual; Infection; Injection of therapeutic agent; Institution; Messenger RNA; Numbers; Patients; Peripheral Blood Mononuclear Cell; Pharmaceutical Preparations; Race; Range; Reporting; Research; Research Personnel; Resources; Source; Staging; T-Lymphocyte Subsets; Taxes; United States; United States National Institutes of Health; Viral Antigens; Viral Load result; Virus; Western Blotting; antiretroviral therapy; burden of illness; mRNA Expression

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HIV/HTLV co-infections occur frequently and in the range of 1-15% among HIV-1 infected individuals. The relationship between levels of HTLV-1/2 viral burden/disease, and effects of antiretroviral treatment, however, is unknown. HTLV1/2 and HIV ELISA positive co-infected individuals from the New Orleans HIV Outpatient Clinic (HOP), were identified and 72 patients enrolled and evaluated in the study, making this the largest co-infected patient cohort study in the United States. The variables analyzed included: HTLV-1/2 proviral load, HTLV-1/2 tax/rex mRNA expression, HIV viral load, HTLV-1/2 viral antigen detection in peripheral blood mononuclear cell (PBMC) cultures, T cell subsets, demographic variables (age, race, gender, reported use of injection drugs) and administration of highly active antiretroviral therapy (HAART). HTLV proviral load was dichotomized into d 20,000 and 20,000 categories for ease of comparison. Among subjects with HIV/HTLV-1 co-infection, an HTLV-1/2 proviral copy number of 20,000 copies/106 PBMCs was significantly associated with a higher absolute CD4 cell count, HTLV-1 vs HTLV-2 western blot positivity, positive HTLV-1/2 PBMC culture , positive tax/rex mRNA, and an HIV viral load less than 10,000 copies/ml. There was no correlation between HTLV-1/2 proviral copy number or tax/rex RNA expression and administration of antiretroviral therapy. HTLV-1/2 proviral burden was significantly higher among HIV/HTLV-1 co-infected, versus HIV/HTLV-2 co-infected individuals. These results suggest that HTLV-1/2 viral burden in PBMCs has an impact on disease staging among HIV-infected individuals. HAART may be of limited value in controlling HTLV-1/2 virus expression in patients with HIV/HTLV-1/2 co-infections.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 HIV/HTLV合并感染经常发生，在HIV-1感染者中的比例为1-15%。 然而，HTLV-1/2病毒负荷/疾病水平与抗逆转录病毒治疗效果之间的关系尚不清楚。 从新奥尔良HIV门诊诊所（HOP）确定了HTLV 1/2和HIV ELISA阳性的合并感染个体，并在研究中招募和评估了72名患者，使其成为美国最大的合并感染患者队列研究。 分析的变量包括：HTLV-1/2前病毒载量、HTLV-1/2 tax/雷克斯mRNA表达、HIV病毒载量、外周血单核细胞（PBMC）培养物中的HTLV-1/2病毒抗原检测、T细胞亚群、人口统计学变量（年龄、种族、性别、报告的注射药物使用）和高效抗逆转录病毒疗法（HAART）的施用。 HTLV前病毒载量被分为d20，000和20，000两类，以便于比较。 在HIV/HTLV-1合并感染的受试者中，HTLV-1/2前病毒拷贝数20，000拷贝/106 PBMC与较高的绝对CD 4细胞计数、HTLV-1与HTLV-2蛋白质印迹阳性、阳性HTLV-1/2 PBMC培养、阳性tax/雷克斯mRNA和HIV病毒载量低于10，000拷贝/ml显著相关。 HTLV-1/2前病毒拷贝数或tax/雷克斯RNA表达与抗逆转录病毒治疗的给予之间没有相关性。 与HIV/HTLV-2共感染个体相比，HIV/HTLV-1共感染个体的HTLV-1/2前病毒负荷显著更高。 这些结果表明，PBMC中的HTLV-1/2病毒负荷对HIV感染者的疾病分期有影响。 HAART在控制HIV/HTLV-1/2合并感染患者的HTLV-1/2病毒表达方面可能价值有限。